Those aiming for above-average market returns often engage in the meticulous process of stock picking. Choosing the right stocks can make a substantial difference in your wealth.
In the latest session, Denali Therapeutics Inc (NASDAQ: DNLI) closed at $15.49 up 1.71% from its previous closing price of $15.23. In other words, the price has increased by $1.71 from its previous closing price. On the day, 2.74 million shares were traded. DNLI stock price reached its highest trading level at $16.19 during the session, while it also had its lowest trading level at $15.33.
Ratios:
For a deeper understanding of Denali Therapeutics Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 10.27 and its Current Ratio is at 10.27. In the meantime, Its Debt-to-Equity ratio is 0.05 whereas as Long-Term Debt/Eq ratio is at 0.04.
On February 11, 2025, Deutsche Bank started tracking the stock assigning a Buy rating and target price of $31.Deutsche Bank initiated its Buy rating on February 11, 2025, with a $31 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Aug 12 ’25 when Schuth Alexander O. sold 2,937 shares for $13.58 per share. The transaction valued at 39,884 led to the insider holds 242,346 shares of the business.
Ho Carole sold 2,937 shares of DNLI for $39,884 on Aug 12 ’25. The Chief Medical Officer now owns 217,391 shares after completing the transaction at $13.58 per share. On Aug 13 ’25, another insider, Ho Carole, who serves as the Chief Medical Officer of the company, sold 806 shares for $14.64 each. As a result, the insider received 11,800 and left with 216,585 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, DNLI now has a Market Capitalization of 2264823808 and an Enterprise Value of 1413849216.
Stock Price History:
The Beta on a monthly basis for DNLI is 1.22, which has changed by -0.3949219 over the last 52 weeks, in comparison to a change of 0.1513431 over the same period for the S&P500. Over the past 52 weeks, DNLI has reached a high of $33.33, while it has fallen to a 52-week low of $10.57. The 50-Day Moving Average of the stock is 8.18%, while the 200-Day Moving Average is calculated to be -12.84%.
Shares Statistics:
For the past three months, DNLI has traded an average of 1.62M shares per day and 1686790 over the past ten days. A total of 145.69M shares are outstanding, with a floating share count of 126.50M. Insiders hold about 13.48% of the company’s shares, while institutions hold 94.10% stake in the company. Shares short for DNLI as of 1753920000 were 12830063 with a Short Ratio of 7.92, compared to 1751241600 on 12457321. Therefore, it implies a Short% of Shares Outstanding of 12830063 and a Short% of Float of 9.8900005.
Earnings Estimates
The dynamic stock of Denali Therapeutics Inc (DNLI) is currently attracting attention from 15.0 analysts actively involved in rating its market status.The consensus estimate for the next quarter is -$0.77, with high estimates of -$0.38 and low estimates of -$0.95.
Analysts are recommending an EPS of between -$2.64 and -$3.3 for the fiscal current year, implying an average EPS of -$3.01. EPS for the following year is -$2.82, with 14.0 analysts recommending between -$1.81 and -$3.68.
